3 Branded Generics Company, Contract Development Specialist and Respiratory Medicines Leader Stocks With a Strong Future Roadmap: Lincoln Pharmaceuticals, Anthem Biosciences and Cipla
- October 29, 2026
- Posted by: Ankit Jaiswal
- Category: Best Stocks
Lincoln Pharmaceuticals, Anthem Biosciences and Cipla: ROE of 11.3% to 19.4% and FY22 to FY26 revenue CAGR of 7.1% to 15.5%. Prices as of 28 Oct 2026.
Quick Answer
The three generics, contract development and respiratory to watch are Lincoln Pharmaceuticals, Anthem Biosciences and Cipla. Their return on equity ranges from 11.3% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 15.5%. Anthem Biosciences leads on both return on equity at 19.4% and revenue growth at 15.5% a year. Prices are based on the 28 October 2026 close, and this article is educational, not investment advice.
Generics, contract development and respiratory offer a focused view of a sector where demand keeps widening. Lincoln Pharmaceuticals, Anthem Biosciences and Cipla cover a branded generics company, a contract development specialist and a respiratory medicines leader.
This list covers three generics, contract development and respiratory with complete current figures: Lincoln Pharmaceuticals, Anthem Biosciences and Cipla. Every figure comes from the latest reported financials and the 28 October 2026 market close. Companies without complete current figures were left out.
Click Here – Get Free Investment Predictions
What Are Generics, Contract Development and Respiratory?
Generics, contract development and respiratory are listed pharmaceutical companies that sell branded generic medicines, develop and manufacture molecules for global pharma clients and lead in respiratory and other chronic care medicines. Their earnings depend on launches, approvals and demand across markets.
Generics, Contract Development and Respiratory at a Glance
| Company | CMP (Rs) | Market Cap (Rs Cr) | P/E | Industry P/E | ROE (%) | D/E |
|---|---|---|---|---|---|---|
| Lincoln Pharmaceuticals | 558.1 | 1,067 | 11.1 | 36.0 | 11.6 | 0.01 |
| Anthem Biosciences | 832.15 | 45,546 | 79.1 | 36.0 | 19.4 | 0.02 |
| Cipla | 1,365.6 | 107,528 | 32.0 | 36.0 | 11.3 | 0.02 |
On valuation, Lincoln Pharmaceuticals and Cipla trade at a P/E below the industry P/E, while Anthem Biosciences trades above it, which reflects the growth the market already expects. Readers comparing generics, contract development and respiratory should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.
Why Do Generics, Contract Development and Respiratory Have a Strong Roadmap in India?
Generics, contract development and respiratory have a strong roadmap in India because rising chronic illness, outsourcing by global drug makers and higher healthcare spending keep widening the market for Indian pharmaceutical firms.
- Branded generics. Doctors prescribe trusted brands.
- Contract work. Global clients outsource development.
- Chronic care. Respiratory medicines see repeat use.
Why Lincoln Pharmaceuticals Features Among These Generics, Contract Development and Respiratory
Among the generics, contract development and respiratory on this list, Lincoln Pharmaceuticals is an Ahmedabad-based maker of branded generics and formulations in India and exports to emerging markets, with products across anti-infectives, respiratory and pain care.
Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%.
In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0.
Roadmap: The company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
What to watch: Track branded product growth, export orders and new launches.
Why Anthem Biosciences Features Among These Generics, Contract Development and Respiratory
Among the formulation, biosciences and respiratory medicine shares on this list, Anthem Biosciences is a research-driven contract development and manufacturing organisation that serves global pharma and biotech customers with discovery, development and manufacturing services.
Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%.
The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0.
Roadmap: The company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
What to watch: Monitor the order pipeline from global customers and the ramp-up of newer manufacturing capacity.
Why Cipla Features Among These Generics, Contract Development and Respiratory
Among the three companies on this list, Cipla is a Mumbai-based pharmaceutical company with strengths in respiratory medicines, anti-infectives and chronic therapies. It sells branded and generic products in India, South Africa, the United States and other markets.
The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0.
Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore.
Roadmap: The company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
What to watch: Follow new product launches in the United States and the growth of key domestic brands.
Lincoln Pharmaceuticals vs Anthem Biosciences vs Cipla on Key Financials
The table below sets the three generics, contract development and respiratory side by side on revenue, profit and margin, using reported figures.
| Company | FY22 Revenue (Rs Cr) | FY26 Revenue (Rs Cr) | Revenue CAGR (FY22-FY26) | FY26 Net Profit (Rs Cr) | FY26 Net Margin |
|---|---|---|---|---|---|
| Lincoln Pharmaceuticals | 482 | 704 | 9.9% | 87.9 | 12.5% |
| Anthem Biosciences | 1,280 | 2,280 | 15.5% | 592 | 26.0% |
| Cipla | 22,044 | 29,045 | 7.1% | 3,870 | 13.3% |
Anthem Biosciences posts the highest return on equity in this group at 19.4%. Cipla has the largest FY26 revenue at Rs 29,045 crore, and Anthem Biosciences shows the fastest revenue growth with a 15.5% compound annual rate.
Key Risks to Check Before Investing in Generics, Contract Development and Respiratory
Every theme carries risks that deserve a check before any decision. For these generics, contract development and respiratory, the main points are:
- Regulatory approvals. Plant inspections and approvals can affect supplies.
- Pricing pressure. Generic prices can change by market.
- Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them.
Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.
Use the Univest Stock Screener to filter generics, contract development and respiratory by market capitalisation, P/E, ROE and growth, and build your own shortlist.
Final Thoughts on Generics, Contract Development and Respiratory
Generics, contract development and respiratory reward patient research into demand, execution and financial strength. Lincoln Pharmaceuticals, Anthem Biosciences and Cipla each have a clear plan to expand. Based on the 28 October 2026 close, Lincoln Pharmaceuticals trades at Rs 558.1, Anthem Biosciences at Rs 832.15 and Cipla at Rs 1,365.6.
Download the Univest iOS App or Univest Android App to track generics, contract development and respiratory, set price alerts and get research-backed stock ideas.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
What are generics, contract development and respiratory?
Ans. Generics, contract development and respiratory are listed pharmaceutical companies that sell branded generic medicines, develop and manufacture molecules for global pharma clients and lead in respiratory and other chronic care medicines. Their earnings depend on launches, approvals and demand across markets. This list looks at three of them, Lincoln Pharmaceuticals, Anthem Biosciences and Cipla, using reported FY22 to FY26 financials and the 28 October 2026 closing prices.
Which generics, contract development and respiratory are covered in this list?
Ans. This list covers Lincoln Pharmaceuticals, Anthem Biosciences and Cipla. Based on the 28 October 2026 close, Lincoln Pharmaceuticals traded at Rs 558.1, Anthem Biosciences at Rs 832.15 and Cipla at Rs 1,365.6. Their return on equity ranges from 11.3% to 19.4%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.1% to 15.5%.
Why do generics, contract development and respiratory have a strong future roadmap in India?
Ans. Generics, contract development and respiratory have a strong roadmap in India because rising chronic illness, outsourcing by global drug makers and higher healthcare spending keep widening the market for Indian pharmaceutical firms. The main drivers are as follows. Branded generics. Doctors prescribe trusted brands. Contract work. Global clients outsource development. Chronic care. Respiratory medicines see repeat use. Together these factors give the companies on this list a visible path for growth over the coming years.
How has Lincoln Pharmaceuticals performed financially?
Ans. Revenue rose from Rs 482 crore in FY22 to Rs 704 crore in FY26, a compound annual growth rate of 9.9%. Net profit grew from Rs 69.4 crore in FY22 to Rs 87.9 crore in FY26, which works out to a compound annual growth rate of 6.1%. In the June 2026 quarter, revenue grew 19.0% year on year to Rs 202 crore, while net profit rose 30.9% to Rs 36.2 crore. The company has a return on equity of 11.6%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 1,067 crore. The stock trades at a P/E of 11.1, below the industry P/E of 36.0. Looking ahead, the company is expanding its branded portfolio and export markets while adding new products. A focus on emerging markets spreads revenue across regions.
How has Anthem Biosciences performed financially?
Ans. Revenue rose from Rs 1,280 crore in FY22 to Rs 2,280 crore in FY26, a compound annual growth rate of 15.5%. Net profit grew from Rs 406 crore in FY22 to Rs 592 crore in FY26, which works out to a compound annual growth rate of 9.9%. The company has a return on equity of 19.4%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 45,546 crore. The stock trades at a P/E of 79.1, above the industry P/E of 36.0. Looking ahead, the company offers an integrated platform from discovery to commercial manufacturing, which makes it a partner for innovator clients. Its biologics, peptides and small-molecule services give it several routes to growth.
How has Cipla performed financially?
Ans. Revenue rose from Rs 22,044 crore in FY22 to Rs 29,045 crore in FY26, a compound annual growth rate of 7.1%. Net profit grew from Rs 2,559 crore in FY22 to Rs 3,870 crore in FY26, which works out to a compound annual growth rate of 10.9%. In the June 2026 quarter, revenue grew 1.6% year on year to Rs 7,330 crore. The company has a return on equity of 11.3%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 107,528 crore. The stock trades at a P/E of 32.0, below the industry P/E of 36.0. Looking ahead, the company is deepening its position in respiratory and complex generic products while expanding its consumer health and domestic prescription brands. A wide global footprint spreads its earnings across several markets.
What risks should investors check before buying generics, contract development and respiratory?
Ans. Investors should check a few risks before buying generics, contract development and respiratory. Regulatory approvals. Plant inspections and approvals can affect supplies. Pricing pressure. Generic prices can change by market. Valuation levels. Some of these companies trade at high earnings multiples, so growth must continue to justify them. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.
Is this list of generics, contract development and respiratory investment advice?
Ans. No. This article is educational and uses publicly available data as of the 28 October 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.
